Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
21 avr. 2015 10h02 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) today announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
17 févr. 2015 17h56 HE
|
Elite Pharmaceuticals, Inc.
Revenues Increase 8.5% Over Prior Quarter
Conference Call Scheduled for Wednesday, February 18 at 11:00 AM EST
NORTHVALE, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc....
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
17 févr. 2015 17h55 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an...
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
12 févr. 2015 14h49 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
15 janv. 2015 10h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
16 déc. 2014 08h38 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
03 déc. 2014 09h55 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
18 nov. 2014 18h24 HE
|
Elite Pharmaceuticals, Inc.
Revenues increase by 8%
Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST
NORTHVALE, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the...
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
13 nov. 2014 17h02 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Announces New Management Appointments
24 oct. 2014 07h15 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 24, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent...